in the Indian setting, however far higher relapse and early mortality 115 rates were still seen when compared to patients not known to be 116 infected with HIV receiving the same regimen. 2, 5 In the Ethiopian 117 setting, high-dose monotherapy with liposomal amphotericin B was 118 associated with a 32% parasitological failure rate in HIV-VL co-119 infected patients. 2 In such cases, repeated treatment with mono-120 therapies may potentially lead to increased resistance and treatment 121 failures, which has already been described with oral miltefosine in 122 the Indian subcontinent. Meanwhile, resistance mechanisms to 123 amphotericin B deoxycholate have already been described in clinical 124 isolates of L. donovani. 125 Based on the synergistic properties of liposomal amphotericin B 126 and miltefosine, the compassionate use of this combination has 127 been suggested for multiple relapses of VL in HIV-VL co-infection. 4 128 Considering the treatment history, this patient was admitted and 129 treated with a concurrent combination of liposomal amphotericin 130 B (AmBisome) in six doses of 5 mg/kg spread over 14 days (total 131 dose 30 mg/kg) and oral miltefosine 50 mg twice daily for 14 days. 132 Lower doses of this combination have already been shown to be 133 safe and effective in immunocompetent patients in the Indian 134 context, 3 and this regimen allowed the entire treatment to be 135 administered under close inpatient supervision without an 136 extended patient stay, which may have major economic con-137 sequences for typical VL patients in the Indian subcontinent.
138 The CD4 count remained persistently low in this patient despite 139 rigid adherence to ART over a 9-month period, during which he 140 relapsed and was treated twice for VL. At the initiation of the final 141 treatment round with combination therapy, his CD4 count was the 142 lowest it had been since ART was initiated at 77 cells/ml, with a 143 very low viral load. Following treatment with this combination 144 regimen, the patient remained relapse-free at 18 months and 145 sustained a CD4 count >350 cells/ml. This suggests that the 146 recovery of immune function that allowed final cure of the VL was 147 not solely attributable to the control of HIV, but rather was in part 148 due to the effective treatment of VL with this combination. This in 149 turn may have broken the vicious cycle of synergy that HIV and VL 150 co-infection has on the immune and hematopoietic systems. 151 The importance of recognizing the special needs of co-infected 152 patients should not be underestimated, and region-specific 153 guidelines need to be developed by the appropriate national 154 programs to recognize the problem and assist physicians in 155 managing this otherwise very challenging scenario. Indeed, all 156 HIV patients with a history of spending significant periods in VL 157 endemic areas should be screened for VL, whilst all patients 158 diagnosed with VL should conversely be screened for HIV. 159 Additionally, the use of monotherapy in those patients at high 160 risk of relapse should be reconsidered. 161 In conclusion, this instructive case suggests that mono-162 therapies with low-dose liposomal amphotericin B, lipid 163 complex amphotericin B, and 28 days of miltefosine may result 164 in treatment failure in HIV-VL co-infected patients, especially in 165 those with low CD4 counts. Combination therapy with liposomal 166 amphotericin B (30 mg/kg) and miltefosine (100 mg per day for 167 14 days) may result in a successful outcome. In the longer term, 168 the appropriate management of HIV-VL co-infected patients 169 may have an important role in reducing the reservoir of the 170 parasite thus working towards the ultimate aim of disease 171 elimination.
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